Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
HKD 4.02
(4.42%)
HKD 4.02
(4.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -359.11 Million CNY | 4.21% |
| 2022 | -374.88 Million CNY | -28.26% |
| 2021 | -292.28 Million CNY | 90.89% |
| 2020 | -3.2 Billion CNY | -384.83% |
| 2019 | -661.79 Million CNY | -343.52% |
| 2018 | -149.21 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -84.52 Million CNY | 0.0% |
| 2024 Q1 | -84.52 Million CNY | 12.33% |
| 2023 FY | -359.11 Million CNY | 4.21% |
| 2023 Q2 | -83.14 Million CNY | 0.0% |
| 2023 Q1 | -83.14 Million CNY | 31.86% |
| 2023 Q4 | -96.41 Million CNY | 0.0% |
| 2023 Q3 | -96.41 Million CNY | -15.97% |
| 2022 Q2 | -63.91 Million CNY | 0.0% |
| 2022 FY | -374.88 Million CNY | -28.26% |
| 2022 Q4 | -122.01 Million CNY | 0.0% |
| 2022 Q3 | -122.01 Million CNY | -90.91% |
| 2022 Q1 | -63.91 Million CNY | 22.34% |
| 2021 Q2 | -68.29 Million CNY | 0.0% |
| 2021 Q3 | -82.29 Million CNY | -20.49% |
| 2021 Q4 | -82.29 Million CNY | 0.0% |
| 2021 FY | -292.28 Million CNY | 90.89% |
| 2021 Q1 | -68.29 Million CNY | 80.56% |
| 2020 FY | -3.2 Billion CNY | -384.83% |
| 2020 Q4 | -351.37 Million CNY | 0.0% |
| 2020 Q3 | -351.37 Million CNY | 13.34% |
| 2020 Q2 | -405.44 Million CNY | 0.0% |
| 2020 Q1 | -405.44 Million CNY | -199.56% |
| 2019 Q2 | -77.05 Million CNY | 0.0% |
| 2019 Q3 | -135.34 Million CNY | -75.64% |
| 2019 Q4 | -135.34 Million CNY | 0.0% |
| 2019 Q1 | -77.05 Million CNY | 0.0% |
| 2019 FY | -661.79 Million CNY | -343.52% |
| 2018 FY | -149.21 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 606.686% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 2181.849% |